Article info
EBM verdict
General medicine
Prevention of cardiovascular disease and renal failure in type 2 diabetes: sodium-glucose cotransporter-2 (SGLT2) inhibitors
- Correspondence to Dr Jack W O’Sullivan, Division of Cardiology, Department of Medicine, Stanford University, Palo Alto, CA 94305, USA; jackos{at}stanford.edu
Citation
Prevention of cardiovascular disease and renal failure in type 2 diabetes: sodium-glucose cotransporter-2 (SGLT2) inhibitors
Publication history
- Accepted July 18, 2019
- First published July 31, 2019.
Online issue publication
March 24, 2020
Article Versions
- Previous version (31 July 2019).
- Previous version (6 September 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.